Abbott completes acquisition of Alere

Abbott has announced the completion of its acquisition of Alere, effective as of today (October 3rd 2017).

The purchase of Alere establishes Abbott as the global leader in the point-of-care testing market, which represents the fastest-growing segment of the $50 billion in vitro diagnostics sector. 

It will also strengthen the company's diagnostics presence and complement the leadership positions it has built across its various other businesses, including medical devices, nutritionals and established pharmaceuticals.

Brian Blaser, executive vice-president for diagnostic products at Abbott, said: "Combined with Abbott's existing point of care business and its leading handheld platform, i-STAT, we now have the broadest point-of-care testing portfolio to help improve care for patients in more parts of the world."

Point-of-care testing is growing rapidly due to the increasing reliance on these devices among healthcare systems, which see them as a way of informing patient care decisions speedily and accurately, particularly in the outpatient setting. 

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.